The Trump administration has finalized a rule that cuts off federal Medicaid and Children’s Health Insurance Program (CHIP) funding for gender-affirming medical care for minors. The rule, issued August 11 by the Centers for Medicare & Medicaid Services (CMS) under Administrator Dr. Mehmet Oz, takes effect October 13, 2026, and blocks federal dollars from paying for puberty blockers, cross-sex hormones, and surgeries for young people.
The change does not ban the care outright. It withdraws the federal government’s share of the cost, leaving states to decide whether to cover the treatments entirely with their own money. For families who depend on Medicaid, that distinction can be the difference between accessing doctor-recommended care and going without it.
What the Rule Does
Under the finalized rule, federal financial participation ends for Medicaid beneficiaries under 18 and CHIP enrollees under 19 who receive gender-affirming medical treatment. CMS built in a limited transition: patients already on hormone therapy can keep federal coverage through a clinically managed tapering period of up to six months, rather than losing support overnight.
The rule is deliberately narrow in one respect. It targets puberty blockers, hormones, and surgeries, but it preserves federal coverage for mental-health and behavioral services, for care related to disorders of sexual development, and for the management of complications. That carve-out is why the policy affects “some,” not all, youth transgender care.
How We Got Here
The rule is the final version of a proposal first floated in December 2025. It is not a law passed by Congress and not an executive order — it is an administrative regulation issued by a federal health agency, which gives it real force but also makes it a target for the courts. Legal challenges are widely expected before the October start date, and advocacy groups have signaled they intend to fight it.
Dr. Oz, the former television personality who now runs CMS, framed the decision as a protective measure. “Children deserve our protection, not experimental interventions that pose serious risks and convey no proven benefits,” he said. Major medical associations, including groups representing pediatricians and endocrinologists, have long taken the opposite view, describing gender-affirming care as evidence-based and, in some cases, medically necessary.
Who Feels the Impact
The families most affected are the ones with the least room to absorb the cost. Medicaid and CHIP exist precisely because those households cannot afford private coverage. When the federal share disappears, a state that chooses not to backfill leaves those families to pay out of pocket — an option that, for many, simply is not realistic.
The rule also shifts who makes the call. Instead of a decision worked out between a patient, their family, and their doctor, coverage now turns on a policy written by political appointees in Washington. Supporters argue that public money should not fund treatments they consider unproven. Critics counter that the government is inserting itself into private medical decisions and singling out one group of patients for reduced coverage.
What This Means for Americans
For most people, the rule will not change their own coverage. But it sets a precedent for how far a federal agency can go in deciding which doctor-recommended treatments public insurance will and will not pay for. Once that line is drawn for one group, the question of who is next becomes very real. The courts, and the states, will now decide how far the policy actually reaches.
Stay informed on the stories that matter most. Follow Your Daily Updates on Facebook and bookmark yourdailyupdates.news for breaking news and analysis.